Literatur
Burstein HJ (2011) Novel agents and future directions for refractory breast cacner. Semin Oncol 38(Suppl 2):17–24
Efeyan A, Sabatini DM (2010) mTOR and cancer: many loops in one pathway. Curr Opin Cell Biol 22:169–76
Baselga J, Semiglazov V, Dam P van et al (2009) Phase 2 randomized study of neoadjuvant everolimus plus letrozol compared with placebo plus letrozol in patients with estrogen receptor-positive breast cancer. J Clin Oncol 27:2630–2637
Motzer RJ, Escudier B, Oudard S et al (2010) Phase 3 trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer 116:4256–4265
Interessenkonflikt
Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Richter-Ehrenstein, C. Everolimus beim metastasierten hormonrezeptorpositiven Mammakarzinom. Onkologe 18, 435–437 (2012). https://doi.org/10.1007/s00761-012-2251-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00761-012-2251-9